Current understanding and management of CAR T cell-associated toxicities
JN Brudno, JN Kochenderfer - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …
haematological malignancies and is being investigated in patients with various solid …
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can
predispose for severe infectious complications. Current grading systems, such as the …
predispose for severe infectious complications. Current grading systems, such as the …
CAR T cell Toxicities: Bedside to Bench-How Novel Toxicities Inform Laboratory Investigations
Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several
are under development. While effective for some cancers, toxicities remain a limitation. The …
are under development. While effective for some cancers, toxicities remain a limitation. The …
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy,
resulting in significant morbidity and mortality. In an effort to standardize reporting, the …
resulting in significant morbidity and mortality. In an effort to standardize reporting, the …
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the
treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent …
treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent …
Recognizing, defining, and managing CAR-T hematologic toxicities
Autologous CAR-T cell therapy (CAR-T) has improved outcomes for patients with B-cell
malignancies. It is associated with the well-described canonical toxicities cytokine release …
malignancies. It is associated with the well-described canonical toxicities cytokine release …
Navigating the prognostic role of transfusions after CAR-T
M Alhomoud, K Rejeski - Blood Advances, 2024 - ashpublications.org
In this issue of Blood Advances, Vic et al 1 report on transfusion support after CD19-directed
chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). To collect …
chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). To collect …
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective
treatment option for several advanced B-cell malignancies. Haematological side-effects …
treatment option for several advanced B-cell malignancies. Haematological side-effects …
Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory …
X Zhou, V Wagner, L Scheller… - British Journal of …, 2024 - Wiley Online Library
Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR)
multiple myeloma (MM) are not completely defined. We prospectively analysed 275 …
multiple myeloma (MM) are not completely defined. We prospectively analysed 275 …
[HTML][HTML] Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients
J Fitzsimons, PA Hagen - Journal of Cancer Metastasis and …, 2024 - oaepublish.com
Multiple myeloma is a neoplastic disorder of plasma cells typically afflicting older individuals.
Despite significant improvements in induction therapy and outcomes for transplant-ineligible …
Despite significant improvements in induction therapy and outcomes for transplant-ineligible …